$0.58
7.24% today
Nasdaq, Apr 02, 10:18 pm CET
ISIN
US00534A1025
Symbol
IVVD

Adagio Therapeutics Inc Stock price

$0.58
-0.36 38.35% 1M
-0.37 39.04% 6M
+0.14 30.69% YTD
-3.23 84.80% 1Y
-3.80 86.78% 3Y
-16.42 96.59% 5Y
-16.42 96.59% 10Y
Nasdaq, Closing price Wed, Apr 02 2025
+0.04 7.24%
ISIN
US00534A1025
Symbol
IVVD
Sector
Industry

Key metrics

Market capitalization $64.78m
Enterprise Value $-3.27m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.02
EV/Sales (TTM) EV/Sales -0.13
P/S ratio (TTM) P/S ratio 2.55
P/B ratio (TTM) P/B ratio 0.96
Revenue (TTM) Revenue $25.38m
EBIT (operating result TTM) EBIT $-176.88m
Free Cash Flow (TTM) Free Cash Flow $-170.63m
Cash position $69.35m
EPS (TTM) EPS $-1.43
P/E forward 4.76
P/S forward 0.37
EV/Sales forward negative
Short interest 8.40%
Show more

Is Adagio Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,807 stocks worldwide.

Adagio Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a Adagio Therapeutics Inc forecast:

2x Buy
67%
1x Hold
33%

Analyst Opinions

3 Analysts have issued a Adagio Therapeutics Inc forecast:

Buy
67%
Hold
33%

Financial data from Adagio Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
25 25
-
100%
- Direct Costs 4.73 4.73
133% 133%
19%
21 21
1,117% 1,117%
81%
- Selling and Administrative Expenses 57 57
27% 27%
225%
- Research and Development Expense 137 137
14% 14%
541%
-174 -174
16% 16%
-685%
- Depreciation and Amortization 3.11 3.11
53% 53%
12%
EBIT (Operating Income) EBIT -177 -177
15% 15%
-697%
Net Profit -170 -170
14% 14%
-670%

In millions USD.

Don't miss a Thing! We will send you all news about Adagio Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Adagio Therapeutics Inc Stock News

Neutral
GlobeNewsWire
7 days ago
WALTHAM, Mass., March 26, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) is pleased to announce the appointment of Ajay Royan to its Board of Directors. Mr. Royan is a venture capitalist focused on transformational companies that have solved critical problems in healthcare, technology, and energy. Mr. Royan's investment firm, Mithril, is a significant long-term holder of Invivyd stock, a...
Neutral
GlobeNewsWire
13 days ago
WALTHAM, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced financial results for the fourth quarter and full year ended December 31, 2024, and recent business highlights.
Neutral
GlobeNewsWire
28 days ago
WALTHAM, Mass., March 05, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced positive, continued, clinically meaningful in vitro neutralization data for PEMGARDA™ (pemivibart) against the currently dominant LP.8.1 variant of SARS-CoV-2. Notably, and consistent with all dominant variants for the past three years, LP.8.1 did not generate any meaningful change to the neutralizat...

Company Profile

Adagio Therapeutics, Inc. engages in the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The firm develops antibodies that can neutralize SARS-CoV-2, SARS-CoV-1, and additional emergent coronaviruses. It offers, ADG20, a monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses. The company was founded by Tillman U. Gerngross, Ren? Russo and Laura Walker on June 3, 2020 and is headquartered in Waltham, MA.

Head office United States
CEO William Duke
Employees 99
Founded 2020
Website invivyd.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today